OncoMed says CMO Dupont has resigned and expects return to Genentech/RocheOncoMed Pharmaceuticals Inc. said early Monday that Chief Medical Officer Jakob Dupont had resigned, effective early 2017, and that he plans a return to Genentech/Roche . The company said it has started a search for its next CMO. Dupont's resignation was due to "personal and family-related issues," OncoMed said. Dupont worked at Roche, and before that Genentech, for about five years, according to his LinkedIn profile, and his return to the company should be "a position of significant responsibility in oncology clinical development," OncoMed said. OncoMed shares, which were not active in pre-market trade, dropped 62.4% year-to-date to $8.48 per share, compared with a 7.2% rise in the S&P 500 .

Stocks end mixed; Dow posts strongest month since March Oil soars on OPEC production-cut agreementThe Dow industrials manages to close at a fractional gain, but other major indexes finish lower Wednesday as an early session rally from the energy sector sputtered out in late trade.

Russell 2000 sees strongest month since October 2011U.S. stocks finished mostly lower on Wednesday, but that didn't stop the Russell 2000 from posting its strongest monthly gain since October 2011. The S&P 500 shed 5.84 points, or 0.3%, to 2,198.82, but remained up 3.4% for the month. The Dow finished flat at 19,124, with Goldman Sachs Group and DuPont Co. the best performers on the blue-chip gauge, which rose 5.4% in November. The Nasdaq Composite Index slid 56.04 points, or 1.1%, to 5,323.68, notching its strongest performance since July. The small-cap Russell 2000 index, lost tk points, or tk% to tk, but rose 11.2% on the month. President-elect Donald Trump's unexpected electoral victory helped spark an aggressive rally, as investors bet that his proposed fiscal policies would help boost economic growth.

Dow, S&P 500, Nasdaq all close at new record highs Russell 2000 also closes at fresh highU.S. stocks close higher at fresh records Monday, aided by a jump in oil prices and a pullback in the dollar, giving the Dow industrials, S&P 500, and Nasdaq their third simultaneous all-time closing highs this year.

EU probing ChemChina's bid for SyngentaBRUSSELS -- The European Union's antitrust watchdog will launch an in-depth probe into China National Chemical Corp.'s plan to buy Syngenta AG to determine if the deal would lower competition for crop-protection products.

Dow Chemical revenue climbs ahead of DuPont dealDow Chemical Co., looking to complete its merger with rival DuPont Co., said revenue rose in the latest period amid growth in its agriculture segment, where sales have lagged behind so far this year. Shares rose 2.8% to $55.26 in premarket trading. On Thursday, Chief Executive Andrew Liveris gave a rosy outlook on Dow's business environment, pointing to "steady growth" in North America and Europe that it sees continuing.

Stock market ends lower after lackluster earnings, drop in consumer confidence Whirlpool tanks after earnings miss Wall Street’s estimatesU.S. stocks on Tuesday finish lower, giving up some of the previous day’s advance, as worries about a lackluster spate of earnings, and a slip in a reading of consumer confidence weighed on market sentiment.

Do lawsuits drive innovation in chemical industry?Lawsuits on health and environmental liability are among the biggest risks affecting the chemical industry. But could they also be one of the main drivers of progress?

DuPont, Dow Chemical merger seen closing in Q1DuPont Co.'s merger with Dow Chemical Co. now appears likely to complete in the first quarter of 2017, later than initially hoped, as antitrust authorities scrutinize a spate of agricultural deals, DuPont's top executive said.

A long-term gold bull wants to see this happen before he buys more Critical information ahead of the U.S. market’s openIf you’ve been waiting for an opportunity to dive back into gold, then you should think twice. A big signal has yet to be unleased on this market.

DuPont lifts yearly profit view as sales increase Chemical giant DuPont Co., looking to wrap up its merger with Dow Chemical Co., boosted its profit outlook for the year as it reported higher sales from its agriculture and performance materials segments in the latest period.

DuPont earnings: What to expectDuPont Co. is scheduled to announce its third-quarter results before the market opens on Tuesday. Here's what you need to know: EARNINGS FORECAST: Analysts expect operating income of 21 cents a share for the third quarter, according to Thomson Reuters, compared with 13 cents a year earlier. REVENUE FORECAST: Revenue of $4.87 billion is forecast for the quarter, versus $4.9 billion a year earlier.

Monsanto earnings top estimates amid Bayer dealMonsanto Co. said it anticipates a return to higher profits next year as the biotech seed maker rolls out new soybean varieties. The St. Louis company, which agreed last month to sell itself to rival Bayer AG for $57 billion in cash, said lean times in agriculture were set to continue. But Monsanto anticipates more farmers in North and South America migrating to its latest seeds in a bid to stay profitable.

U.S. stocks close lower on concerns of ECB tighteningU.S. stocks finished down Tuesday following a report that the European Central Bank could end its quantitative easing efforts sooner than planned. The Dow Jones Industrial Average fell 85.40 points, or 0.5%, to close at 18,168.45, weighed down by shares of 3M Co. and DuPont . The S&P 500 Index declined 10.71 points, or 0.5%, to finish at 2,150.49, with the utilities and telecom sectors leading the index lower. The Nasdaq Composite index closed down 11.22 points, or 0.2%, at 5,289.66.

These may be the most beautiful cars in the world ‘Rolling Sculptures’ exhibit shows off Art Deco cars from the 1930s and ’40sIf you could abandon practicality, performance and price and design cars solely with beauty in mind, you would find yourself in one period of automotive history — the Art Deco movement of the 1920s through 1940s.

Charley Ellis gives the simple reasons index investing winsProponents of active management are investors of a certain age who have done well at it in the past. I'm not going to deny that active once worked fine, only that it doesn't work anymore, except for a tiny fraction of highly unusual investors.

Stocks pare gains to end flat ahead of Fed, BOJ decisions Home-building stocks slump after poor housing-starts dataU.S. stocks on Tuesday end little-changed, paring modest gains into the close, as traders grow cautious on the eve of a pair of major central-bank decisions.

How a Bayer-Monsanto merger will wind up costing you at the grocery store For one thing, expect pricier soy milk. For one thing, expect pricier soy milk.It’s just one of several mergers in an industry already dominated by only a few companies.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc. All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More information on NASDAQ traded symbols and their current financial status. Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is at least 60-minutes delayed. All quotes are in local exchange time.